GLP-1 Drug Users Identified as Potential Swing Voting Bloc Ahead of 2026 Midterms
New polling from the firm Cygnal identifies Americans using GLP-1 medications — including Ozempic and Wegovy — as a potentially significant voting constituency ahead of the 2026 midterm elections. The drugs, originally developed to treat diabetes, have expanded into widespread use for weight management and metabolic health. The Cygnal data suggest this group is growing and that voters see GLP-1 use largely as a personal or medically responsible choice rather than a moral failing.
Single source · Not corroborated
A Washington Examiner opinion piece authored by former White House press secretary Sean Spicer argues that GLP-1 medication users represent an emerging voting bloc that neither party has fully courted, and that Republicans are positioned to win them over.
The piece cites polling conducted by Cygnal, describing GLP-1 users as often working-age, previously disengaged Americans who are practical in their political expectations and focused on family health. Cygnal pollster Alex Tarascio is quoted as saying the data show "very little appetite for judging people over a GLP-1 decision" and that skepticism about the drugs centers on cost and access rather than ethics.
Dr. Jessica Duncan, described as chief medical officer of Ivim Health and a board-certified obesity medicine physician, is quoted in the piece stating that "treating obesity is real medical care" and that GLP-1 medications are "one effective tool" when accompanied by ongoing clinical follow-up. The piece also features commentary from Tiffany Ryder, described as a certified physician assistant with emergency medicine experience.